

Are CleanTech and Bio-renewables *Back to Stay?*

Luncheon/Webcast of June 5, 2014 at the Yale Club

Abstract

- Will the promise of cleantech and bio-renewables finally deliver new products?
- Will the growth of natural gas from shale slow down the advances of Cleantech?
- What has been the net impact of the great recession on biotech innovation?

The cleantech and bio-renewables revolution promised to dramatically change the industrial, materials, energy, food and healthcare sectors to address the increasing demands of population growth to 9 billion people by 2050, climate change and efficient and sustainable use of natural resources. The convergence of breakthrough technologies in agribusiness, biotechnology, chemistry, data analytics and energy, the alternate uses of renewable feed-stocks and a strong consumer demand for sustainable and healthy products have been long term drivers underlining these changes.

Many corporations such as Monsanto, DuPont, DSM and others have undergone dramatic evolutions, investing in life sciences and startup companies to align their businesses to address these trends and capture a \$3-5 trillion market opportunity. However, the great recession of 2007, which limited funding for innovation, and the rapid growth of natural gas from shale, which has lowered the price of energy and feed stocks, has slowed advances in the short term. With a recovering economy and renewed interest from strategic partners and investors, evolved startups and long term secular trends intact the cleantech and bio-renewables industries have started to reemerge.

Join us and gain unique insights from experts on the impact that disruptive and revolutionary advances in cleantech and bio-renewables will have on the global economy. The panel includes Bob Wedinger, PhD, Brent Erickson, Nathan Tinker, PhD and Paul Pospisil, PhD.

Biographies



Bob Wedinger is President & Chief Executive Officer of Rennovia Inc. Dr. Wedinger has over 25 years of experience in the specialty-chemicals industry. After a post-doctoral research appointment at Harvard University, Dr. Wedinger joined FMC Corporation as a Discovery Chemist in the Agricultural Chemicals Group. He held a number of positions of increasing responsibility in the Specialty Chemicals Group of FMC before moving to Honeywell International (Allied Signal). At Honeywell, Dr. Wedinger rose from Director of Research to Vice President and General Manager of the Pharmaceutical Fine Chemicals business. Dr. Wedinger then served as Vice President and General Manager of the Consumer Products and the Performance Materials businesses at JM Huber. Most recently, Bob was the Chief Business Officer and Group President, Performance Materials, at Chemtura Corporation, a \$3.7 billion specialty-chemicals company. Dr. Wedinger earned a Ph.D. in Physical Organic Chemistry from the State University of New York at Stony Brook.



Brent Erickson is Executive Vice President, of the Industrial and Environmental Section at the Biotechnology Industry Organization (BIO) representing more than 1,200 biotechnology companies, academic institutions, and state biotechnology centers across the U.S. and in more than 30 other nations. Mr. Erickson holds a B.S. in Biology and an M.A. in International Studies. After completing his undergraduate degree, he was involved in fossil fuel research for three years at the U.S. Department of Energy's Laramie Energy Technology Center.

Diamond Sponsor

HUNTSMAN

Platinum Sponsors

Grace Matthews

Huntsman-Lion Capital

Mexichem

Media Partner

American
 Chemistry
 Council™

NEW YORK
 BIO

URBAN
 FUTURE
 LAB



Event Schedule

Location:

Yale Club
 50 Vanderbilt Avenue, NYC
 (between 44th and 45th
 Streets)

Event Times: (EDT)

11:30 am - 12:00 noon
 Registration and
 Networking

12:00 noon - 1:00 pm
 Luncheon

1:00 pm - 2:00 pm
 Presentation & Webcast

Luncheon Fees (*):

\$100 for Non-members
 \$70 for 2014 members
 Check for Early-bird
 discounts .

Webcast : \$40

Luncheon/Webcast of June 5, 2014 at the Yale Club

Biographies (continued)

Mr. Erickson was legislative assistant of U.S. Senator Alan K. Simpson (R-WY). In 1996, Mr. Erickson joined the American Petroleum Institute (API) as a Washington representative. Mr. Erickson joined BIO in 2000 initial as Director, and then as VP in 2001 and EVP in 2005. Mr. Erickson serves on several board including: as vice-chair of the Organization for Economic Cooperation and Development's Task Force on Biotechnology, the Western Research Institute, the advisory board of the Energy Biosciences Institute (EBI) (UC Berkeley, the Lawrence Berkeley National Laboratory, the University of Illinois, and BP).



Nathan Tinker Nathan Tinker has been Executive Director of NewYorkBIO since 2007. As Executive Director, Nathan serves as a spokesman and advocate for the state's industry. He has more than 20 years of experience in working with both global and emerging technology companies. Prior to joining NYBA, he served as Executive Director of the Sabin Vaccine Institute Cancer Vaccine Consortium and as the Director of the Nanotechnology and Biotechnology Practice at Antenna Group. Before that, Dr. Tinker was Co-Founder and Executive Vice President of the NanoBusiness Alliance. Dr. Tinker began his career in market research serving such clients as Apple, Sprint, Cantor Fitzgerald, DaimlerChrysler, Yahoo! and CSX. Dr. Tinker is in the advisory boards of Physicians Interactive Holdings, Viral Genetics, Versilant Technologies and Namar Consulting, as well as with non-profit groups, including Nanotechnology Commercialization Association.



Paul Pospisil is a Senior Client Partner, Global Life Sciences at KornFerry. His primary focus is to assist biotechnology and biopharmaceutical companies in recruiting for positions such as chief executive officer, chief business officer, head of research and development and other key executives. With over fifteen years in the industry as a successful executive and investor, Dr. Pospisil brings a thoughtful perspective to executive search, shaped by a breadth of experiences in new product development, business development, financings, strategy, company building, operational leadership and board functions from start-up, growth to mature biotechnology and biopharmaceutical companies. Prior to joining Korn Ferry, Dr. Pospisil was a co-founder and managing partner of both Aduro Capital LLC, an investment management company focused on the public healthcare sector and Aduro Partners LLC, an advisory firm focused on helping venture-backed and public life science companies assess, evaluate, partner opportunities and build businesses. He has worked at Atlas Venture, Millennium Pharmaceuticals and Altus Biologics. Dr. Pospisil holds a PhD in organic chemistry from Harvard University and a bachelor's degree in biochemistry from NYU. He attended Harvard Business School's Program for Management Development (PMD).

CM&E - Winner of ACS



Global Engagement

Register Now at www.cmeacs.org

Diamond Sponsor

HUNTSMAN

Platinum Sponsors

Grace Matthews

Huntsman-Lion Capital

Mexichem

Media Partners

American
 Chemistry
 Council™

NEW YORK
BIO

URBAN
 FUTURE
 LAB



About CM&E

Established in 1954, CM&E is a topical group of the American Chemical Society's New York Section. ACS, founded in Manhattan in 1876 and chartered by the U.S. Congress, is the world's largest scientific society with over 160,000 members and the premier global home for chemists, chemical engineers and related professions.

CM&E focuses on exciting global trends, vibrant multi-disciplinary networking and actionable insights, by organizing monthly luncheons and webcasts in midtown NYC where thought leaders present original research and cutting-edge outlooks on business, economy, and technology in energy, materials & life science. CM&E audience includes professionals from industry, investment, academia, government, media and supranational organizations.